RecallRadar

FDA Drug recall D-0242-2026

Noxafil Powdermix (posaconazole) for Delayed-Release Oral Suspension, 300 mg, 8 packets per carton, Rx Only, Manufactured for: Merck Sharp…

On 2025-12-31 the FDA classified a Class II recall of Noxafil Powdermix (posaconazole) for Delayed-Release Oral Suspension, 300 mg, 8 packets per carton, Rx Only, Manufactured for: Merck Sharp… by Merck Sharp And Dohme, citing presence of particulate matter: potential presence of metal particulates in the product.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0242-2026
ClassificationClass II
Statusongoing
Initiated2025-12-12
Published2025-12-31
Last updated2026-09-13 11:52 UTC
CompanyMerck Sharp And Dohme
DistributionUS

Product

Noxafil Powdermix (posaconazole) for Delayed-Release Oral Suspension, 300 mg, 8 packets per carton, Rx Only, Manufactured for: Merck Sharp & Doohme LLC, Rahway, NJ 07056 USA, Manufactured by: N.V. Organon, 5349 AB Oss, The Netherlands, a subsidiary of Organon & Co., Jersey City, NJ 07302, USA NDC 0085-2224-02.

Reason

Presence of particulate matter: potential presence of metal particulates in the product.

Identifiers

ndc0085-1328-01
ndc0085-4324-02
ndc0085-4331-01
ndc0085-2224-01
ndc0085-2224-02
code_infoLot#: Z012339, Z010344, Z009908, Z009909, Exp Date 12-31-2026

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: ongoing.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0242-2026%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.